- Home
- NEO vs HRMY Comparison
NEO vs HRMY Comparison
Compare NEO & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEO
- HRMY
- Stock Information
- Founded
- NEO 2001
- HRMY 2017
- Country
- NEO United States
- HRMY United States
- Employees
- NEO N/A
- HRMY N/A
- Industry
- NEO Precision Instruments
- HRMY Biotechnology: Pharmaceutical Preparations
- Sector
- NEO Health Care
- HRMY Health Care
- Exchange
- NEO Nasdaq
- HRMY Nasdaq
- Market Cap
- NEO 2.3B
- HRMY 2.0B
- IPO Year
- NEO 1999
- HRMY 2020
- Fundamental
- Price
- NEO $14.18
- HRMY $40.46
- Analyst Decision
- NEO Strong Buy
- HRMY Strong Buy
- Analyst Count
- NEO 10
- HRMY 8
- Target Price
- NEO $20.56
- HRMY $55.00
- AVG Volume (30 Days)
- NEO 1.2M
- HRMY 596.7K
- Earning Date
- NEO 02-18-2025
- HRMY 02-20-2025
- Dividend Yield
- NEO N/A
- HRMY N/A
- EPS Growth
- NEO N/A
- HRMY N/A
- EPS
- NEO N/A
- HRMY 2.11
- Revenue
- NEO $644,118,000.00
- HRMY $681,879,000.00
- Revenue This Year
- NEO $12.98
- HRMY $24.79
- Revenue Next Year
- NEO $9.94
- HRMY $19.00
- P/E Ratio
- NEO N/A
- HRMY $19.29
- Revenue Growth
- NEO 12.06
- HRMY 25.83
- 52 Week Low
- NEO $12.13
- HRMY $28.14
- 52 Week High
- NEO $19.11
- HRMY $41.61
- Technical
- Relative Strength Index (RSI)
- NEO 40.28
- HRMY 75.22
- Support Level
- NEO $13.93
- HRMY $35.72
- Resistance Level
- NEO $16.18
- HRMY $37.16
- Average True Range (ATR)
- NEO 1.13
- HRMY 1.29
- MACD
- NEO -0.33
- HRMY 0.60
- Stochastic Oscillator
- NEO 29.37
- HRMY 93.95
About NEO NeoGenomics Inc.
NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Advanced Diagnostics. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. Advanced Diagnostics segment supports pharmaceutical firms in their drug development programs by supporting various clinical trials and research. For Clinical Services, Its specialized diagnostic services are performed based on an online test order or a written test requisition form. The company generates majority of its revenue from Clinical Services.
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant), is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and used for the treatment of cataplexy in adult patients with narcolepsy.